Avadel Pharmaceuticals plc (AVDL)
After hours:
| Previous close | 15.94 |
| Open | 15.92 |
| Bid | 15.48 x 100 |
| Ask | 15.52 x 100 |
| Day's range | 15.40 - 16.00 |
| 52-week range | 9.50 - 19.09 |
| Volume | |
| Avg. volume | 1,290,582 |
| Market cap | 1.489B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.82 |
| Earnings date | 04 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.65 |
Insider MonkeyAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript May 8, 2024 Avadel Pharmaceuticals plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2024 Earnings Call. At this time, all participants are […]
GuruFocus.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
Insight into Avadel Pharmaceuticals' Q1 Financial Performance and Strategic Updates
GlobeNewswireAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 0
